{"id":458,"date":"2015-01-08T08:10:47","date_gmt":"2015-01-08T08:10:47","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=458"},"modified":"2018-10-06T05:10:24","modified_gmt":"2018-10-06T05:10:24","slug":"comparative-study-on-the-efficacy-of-artesunate-plus-amodiaquine-combination-act-and-amodiaquine-plus-sulfadoxine-pyrimethamine-combination-non-act-in-the-treatment-of-acute-uncomplicated-malaria","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol1no2\/comparative-study-on-the-efficacy-of-artesunate-plus-amodiaquine-combination-act-and-amodiaquine-plus-sulfadoxine-pyrimethamine-combination-non-act-in-the-treatment-of-acute-uncomplicated-malaria\/","title":{"rendered":"Comparative Study on the Efficacy of Artesunate Plus Amodiaquine Combination (act) and Amodiaquine Plus Sulfadoxine-Pyrimethamine Combination (non-act) in the Treatment of Acute Uncomplicated Malaria in Enugu State, Nigeria."},"content":{"rendered":"

Introduction<\/strong><\/p>\n

The increasing resistance to Chloroquine (CQ) in extent and severity has necessitated the emergence of alternative cheap and available regimens to control programmes in developing countries, particularly Sulfadoxine-Pyrimethamine (SP) and Amodiaquine (AQ) as monotherapy1,2,3<\/sup> or combination of Amodiaquine and Sulfadoxine -Pyrimethamine (AQ + SP) in the treatment of Chloroquine resistant malaria4<\/sup>. Since the first proven case of Chloroquine resistance by an African strain of P<\/em>.falciparum<\/em> was reported from East-Africa5<\/sup>, there has been a persistent report of increasing rate of resistance all over Sub-Saharan Africa. However, the ever increasing resistance to these cheap and readily available alternative regimens has necessitated the need for regular evaluation of the efficacy of these chemotherapeutic agents in the treatment of acute uncomplicated malaria in children. This study attempts to evaluate the current status in respect of clinical efficacy of SP and AQ as monotherapy or in combination as AQ + SP in the treatment of uncomplicated P<\/em>.falciparum<\/em> malaria among under 5 children in Enugu, Nigeria.<\/p>\n

Patients and Methods<\/strong><\/p>\n

Patients (n = 180) enrolled in this study were selected by stratified random sampling from children with clinically characterized uncomplicated malaria aged 6 to 59 months (M:F = 1:1.37) who presented at Amafor primary healthcare facility, Ugbawka; a rural farming population with high endemicity of malaria transmission under the Asu Nkanu Local Health Authority of Enugu State. They presented with a history of fever in the preceding 24 to 48 hours or axillary temperature \u2265 37.50<\/sup>C and parasitemia > 2000 asexual forms\/mL of blood. Patients with concomitant illness, intense vomiting, recent history of convulsion, lethargic or unconscious state and sickle cell anaemia were excluded. Ethical clearance was obtained and informed consent of the parent or guardian for each child was sought. The patients were subsequently assigned randomly to any of the drug treatment groups: SP, AQ or AQ + SP. Thus, 60 patients were allotted to each treatment group. Drug dosages were computed using the weight of the patients. AQ was given at a dose of 10mg\/kg daily for 3 days and SP at 25mg\/kg as single dose on Day O. Drugs were administered orally by direct observation and monitored by the clinician to ensure they were not vomited. Drugs were re-administered within 1 hour following initial vomiting but withdrawn from the study with another episode of vomiting.\u00a0 Patients were followed up for two weeks after treatment. Evaluation of response carried out on days 1,2,3,7 and 14 in accordance with WHO criteria6<\/sup>.\u00a0 Patients who showed features of treatment failure were salvaged using Artemether-Lumefantrine as rescue drug. Data obtained were statistically analyzed using Student t<\/em>-test and presented in tabular form.<\/p>\n

Results<\/strong><\/p>\n

Tables 1 and 2, as shown depicted the therapeutic response of patients in the various treatment groups. In the AQ + SP treatment group, mean Fever Clearance Time (FCT) of 28.3\u00b12.3 hours differed significantly (P<0.05) from 41.2\u00b12.3 hours and 54.6\u00b12.5 hours in Amodiaquine (AQ) and Sulfadoxine-Pyrimethamine (SP) treatment groups respectively. The mean Parasite Clearance Time (PCT) given as 3.7\u00b10.15 days in the AQ + SP group differed significantly (P<0.05) from 6.1\u00b10.15 days and 8.3\u00b10.21 days in AQ and SP respectively. Similarly mean Radical Cure Rate (RCR) in AQ + SP was given as 100% compared to 83.5\u00b10.34% and 73.8\u00b10.44% in AQ and SP groups respectively. There was no reported treatment failure in the AQ + SP group whereas it was given as 26.2\u00b10.44% and 16.5\u00b10.34% in the SP and AQ treatment groups respectively.\u00a0 However, as depicted in tables 3 to 5, there was no statistically significant difference (P>0.05) in the haematocrit and axillary temperature at initial presentation, Day O and post-treatment, Day 14 in the various treatment groups.<\/p>\n

Table 1: \u00a0Therapeutic Response of Patients in the Sp and Aq + Sp Treatment Groups.<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<\/td>\n\u00a0SP<\/strong><\/td>\nAQ+SP<\/strong><\/td>\nP<\/em><\/strong>-Value<\/strong><\/td>\n<\/tr>\n
<\/td>\n(Mean+SEM)<\/strong><\/td>\n(Mean+SEM)<\/strong><\/td>\n\u00a0<\/em><\/strong><\/td>\n<\/tr>\n
Fever Clearance Time (Hrs)<\/td>\n54.6\u00b12.5<\/td>\n28.3\u00b12.3<\/td>\n<0.05<\/td>\n<\/tr>\n
Parasite Clearance Time (Days)<\/td>\n8.3\u00b10.21<\/td>\n3.7\u00b10.15<\/td>\n<0.05<\/td>\n<\/tr>\n
Radical Cure Rate (%)<\/td>\n73.8\u00b10.42<\/td>\n100\u00b10.0<\/td>\n<0.05<\/td>\n<\/tr>\n
Treatment Failure Rate (%)<\/td>\n26.2\u00b10.42<\/td>\n0\u00b10.0<\/td>\n<0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 2: Therapeutic Response Of Patients In The Aq And Aq + Sp Treatment Groups.<\/strong><\/p>\n\n\n\n\n\n\n\n
<\/td>\n\u00a0AQ<\/strong><\/p>\n

(Mean+SEM)<\/strong><\/td>\n

AQ+SP<\/strong><\/p>\n

(Mean+SEM)<\/strong><\/td>\n

P<\/em><\/strong>-Value<\/strong><\/p>\n

\u00a0<\/strong><\/td>\n<\/tr>\n

Fever Clearance Time (Hrs)<\/td>\n41.2\u00b12.3<\/td>\n28.3\u00b12.3<\/td>\n<0.05<\/td>\n<\/tr>\n
Parasite Clearance Time (Days)<\/td>\n6.1\u00b10.15<\/td>\n3.7\u00b10.15<\/td>\n<0.05<\/td>\n<\/tr>\n
Radical Cure Rate (%)<\/td>\n83.5\u00b10.34<\/td>\n100\u00b10.0<\/td>\n<0.05<\/td>\n<\/tr>\n
Treatment Failure Rate (%)<\/td>\n16.5\u00b10.34<\/td>\n0\u00b10.0<\/td>\n<0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 3:\u00a0 Pre And Post\u2013Treatment Haematocrit and Axillary Temperature of Patients it The Sp Treatment Group.<\/strong><\/p>\n\n\n\n\n\n
<\/td>\nPre-Treatment, DO<\/td>\nPost-Treatment, D14<\/td>\nP<\/em> – Value<\/td>\n<\/tr>\n
Haematocrit (%)<\/td>\n27.4+<\/u>2.2<\/td>\n28.6 +<\/u> 2.2<\/td>\n>0.05<\/td>\n<\/tr>\n
Axillary Temp (o<\/sup>C)<\/td>\n38.7+<\/u>1.6<\/td>\n37.4+<\/u>1.5<\/td>\n>0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 4:\u00a0 pre and post\u2013treatment haematocrit and Axillary temperature of patients in the aq treatment group.<\/strong><\/p>\n\n\n\n\n\n
\u00a0<\/strong><\/td>\nPre-Treatment, DO<\/strong><\/td>\nPost-Treatment, D14<\/strong><\/td>\nP<\/em> – Value<\/strong><\/td>\n<\/tr>\n
Haematocrit (%)<\/strong><\/td>\n28.2+<\/u>2.5<\/td>\n29.7 +<\/u> 2.5<\/td>\n>0.05<\/td>\n<\/tr>\n
Axillary Temp (o<\/sup>C)<\/strong><\/td>\n38.4+<\/u>1.6<\/td>\n37.2+<\/u>1.5<\/td>\n>0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 5:\u00a0 Pre and Post\u2013Treatment Haematocrit And Axillary Temperature of Patients in the Aq + Sp Treatment Group.<\/strong><\/p>\n\n\n\n\n\n
<\/td>\nPre-Treatment, DO<\/strong><\/td>\nPost-Treatment, D14<\/strong><\/td>\nP<\/em> – Value<\/strong><\/td>\n<\/tr>\n
Haematocrit (%)<\/strong><\/td>\n28.9+<\/u>2.5<\/td>\n30.1 +<\/u> 2.5<\/td>\n>0.05<\/td>\n<\/tr>\n
Axillary Temp (o<\/sup>C)<\/strong><\/td>\n39.1+<\/u>1.6<\/td>\n37.0+<\/u>1.5<\/td>\n>0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n


\nDiscussion<\/strong><\/p>\n

It is worthy of note that the ideal antimalarial should not only promptly clear parasitemia, fever or other symptoms of malaria, but should also prevent the generation of gametocytes, from asexual forms during treatment7<\/sup>. It has been shown in this study that SP is significantly less effective than AQ or AQ + SP in clearing parasitemia or fever in children with acute uncomplicated malaria. Progressive decline in sensitivity of P<\/em>.falciparum<\/em> to SP has been reported for other similar studies8,9<\/sup>. Fever Clearance Time (FCT) of 54.6\u00b12.5 hours in SP and 41.2\u00b12.3 hours in AQ corroborates findings in other studies. Results clearly showed that AQ + SP combination was significantly (P<0.05) more effective than monotherapy with SP or AQ. Sulfadoxine-pyrimethamine selectively inhibits plasmodial dihydrofolate reductase enzyme in folate synthesis. Thus, a treatment regimen combining amodiaquine, a 4-aminoquinoline and effective blood schizonticide with the prolonged parasiticidal effect of SP seems logical; as it takes advantage of the antipyretic and anti-inflammatory effects of the 4-aminoquinoline. The modulating effect of AQ on enhanced production of premature young gametocytes by SP may provide supporting argument for the use of AQ + SP combination therapy7<\/sup>.\u00a0 AQ + SP has shown excellent anti-malarial efficacy in most African studies, even in those from regions such as East-Africa, where levels of resistance to each component drug are high10<\/sup>. In a study where the monotherapy of AQ and SP was compared with their combinations AQ + SP, a cure rate of 100% was recorded. Also in another comparative study of AQ and SP as monotherapy and combination respectively in Southern Cameroon, a cure rate of 100% was reported for the combination and 83% for the individual monotherapy11<\/sup>. The above corroborates findings in this study which reported a cure rate of 100%, 83.5% and 73.8% for the AQ + SP combination, AQ and SP as monotherapy respectively. It has been further suggested that AQ + SP combination might be especially useful in West Africa, where resistance to AQ + SP combination had more than 94% efficacy against uncomplicated malaria in Nigeria, Ghana and Burkina Faso4,12,13 <\/sup>. Treatment failure of 26.2% reported in this study for SP is low compared to 36.4% in another study in the\u00a0\u00a0 South-East, Nigeria14<\/sup>. This sharply contrasts with treatment failure of 16.5% and 0% reported in this study for AQ and AQ + SP combination. Thus, the treatment failure reported for SP in this study is slightly higher than 25% level recommended for centers in the high endemicity of malaria transmission15<\/sup>. In view of the low efficacy of SP reported in this study, associated with treatment failure beyond the acceptable level of 25% given by WHO, it is recommended that SP be withdrawn as anti-malarial drug in use for the study area. The treatment failure of 16.5% reported for AQ as monotherapy is still above the 10% margin recommended for change of first line drug. Thus, its continuous use will create an apparent well-being but engender a tendency to chronic malaria morbidity in the study population. The use of AQ + SP combination should be encouraged as a result of its relatively high cure rate reported as 100% in this study. The combination is safe, highly effective and a viable option that can ensure the therapeutic lifespan of these drugs. It is, therefore, strongly recommended as the treatment of choice for uncomplicated P.falciparum <\/em>malaria especially in under five children in Enugu, Nigeria.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Olliaro P., Nevill C., Le Bras J., Ringwald P., Mussamo P. and Brasseur P. (1996). Systematic review of amodiaquine treatment in uncomplicated malaria. 348: 1196\u20131201.<\/li>\n
  2. Brasseur P., Guiguemde R., Diallo S., Guiyedi V., Kembila M., Ringwald P. and Olliaro P. (1999). Amodiaquine remains effective for treating uncomplicated malaria in West and Central Africa. Trans R Soc Trop Med Hyg.<\/em> 93:645\u2013650.<\/li>\n
  3. Sowunmi A., Ayede A.I., Falade A.G., Ndikum V.N., Sowunmi Adedeji A.A., Falade C.O., Happi T.C. and Oduola A.M.J (2001). Randomized comparison of chloroquine and amodiaquine in the treatment of uncomplicated, Plasmodium falciparum<\/em> malaria in children. Ann Trop Med Parasitol<\/em>. 95: 549\u2013558.<\/li>\n
  4. Sowunmi A. (2002). A randomized comparison of chloroquine, amodiaquine and their combination in the treatment of acute uncomplicated Plasmodium falciparum<\/em> malaria in children. Ann Trop Med Parasitol<\/em>. 96: 227\u2013238.<\/li>\n
  5. Staedke S.G, Kamya M.R., Dorsey G., Gasasira A., Ndeezi G., Charlebois E.D. and Rosenthal P.J. (2001). Amodiaquine, Sulfadoxine-Pyrimethamine and combination therapy for treatment of uncomplicated falciparum<\/em> malaria in Kampala, Uganda: a randomized trial. Lancet. <\/em>358: 368\u2013374.<\/li>\n
  6. WHO \u2013 World Health Organisation (2006).\u00a0 Guidelines for the treatment of malaria.\u00a0 WHO Press, Geneva<\/em>. 266pp.<\/li>\n
  7. Sowunmi A., Adedeji A.A., Gbotosho G.O., Fateye B.A. and Happi T.C (2006). Effects of sulfadoxine-pyrimethamine, chloroquine plus chlorpheniramine, and amodiaquine plus sulfadoxine-pyrimethamine on gametocytes during and after treatment of acute uncomplicated malaria in children. Mem Inst Oswaldo Cruz.<\/em> 101(8): 887\u2013893.<\/li>\n
  8. Falade C.O., Salako L.A., Sowumni A., Oduola A.M.J. and Larcier P. (1997). Comparative efficacy of halofantrine, chloroquine and sulfadoxine-pyrimethamine in the treatment of acute uncomplicated P.falciparum <\/em>malaria in Nigerian children. Tran R Soc Trop Med Hyg<\/em>. 91: 58 – 62.<\/li>\n
  9. Sibley C.H., Hyde J.E., Sims P.F.G., Plowe C.V., Kublin J.G., Mberu E. K., Cowman A. F., Winstanley P.A., Watkins W.M. and Alexis M.N. (2001). Sulfadoxine-pyrimethamine resistance in P.falciparum: <\/em>what next. Trends Parasitol<\/em>. 17:582\u2013588.<\/li>\n
  10. Schellemberg D., Kahigwa E., Drakeley C., Malende A., Wigayi J., Msokame C., Aponte J.J, Tanner M., Mshinda H., Menendez C. and Alonso P.L. (2002). The safety and efficacy of sulfadoxine-pyrimethamine, <\/em>amodiaquine and their combination in the treatment of uncomplicated P.falciparum <\/em>malaria. Am J<\/em> Trop Med Hyg<\/em>. 67:17-23.<\/li>\n
  11. Basco L.K., Same-Ekobo A., Ngane V.F., Ndounga M., Metoh T., Ringwald P. and Soula G. (2002). Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine + amodiaquine combination against uncomplicated Plasmodium falciparum<\/em> malaria in young children in Cameroon. Bull World Health Organ<\/em>. 80: 538 \u2013 545.<\/li>\n
  12. Mockenhaupt F.P., Ehrhardt S., Dzisi S.Y., Teun Bousema J., Wassilew N., Schreiber J., Anemana S.D., Cramer J.P., Otchwemah R.N., Sauerwein R.W., Eggelte T.A. and Bienzle U. (2005a). A randomized placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health. <\/em>\u00a010:512 \u2013 520.<\/li>\n
  13. Zongo I., Dorsey G., Rouamba N., Dokomajilar C., Lankoande M., Ouedraogo J.B and Rosenthal P.J. (2005). Amodiaquine, sulfadoxine-pyrimethamine and combination therapy for uncomplicated P.falciparum<\/em> malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg<\/em>. 73:826 \u2013 832.<\/li>\n
  14. Okafor H. U and Oguonu T. (2004). Comparative evaluation of the efficacy of chloroquine and sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in children under five years in a rural population of Enugu State. Journal of College of Medicine. <\/em>9(2): 77 \u2013 81.<\/li>\n
  15. White N.J. (1998). Drug resistance in malaria. Brit Med Bull<\/em>. 54: 703 \u2013 715.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction The increasing resistance to Chloroquine (CQ) in extent and […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-458","post","type-post","status-publish","format-standard","hentry","category-vol1no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=458"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/458\/revisions"}],"predecessor-version":[{"id":13183,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/458\/revisions\/13183"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}